{"id":925442,"date":"2026-01-08T10:03:45","date_gmt":"2026-01-08T15:03:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/"},"modified":"2026-01-08T10:03:45","modified_gmt":"2026-01-08T15:03:45","slug":"important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/","title":{"rendered":"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf"},"content":{"rendered":"
\n

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) — <\/p>\n

\n
\n Cytokinetics, Inc. (NASDAQ: CYTK):<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased<\/strong>
\n Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to <\/strong>
\n December 27, 2023,<\/strong>
\n and still hold shares today, <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085.<\/strong>\n <\/p>\n

\n WHY? <\/strong>As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its officers made materially false and misleading statements on to the market, Specifically, on\u00a0March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration (“FDA”) had decided not to convene an advisory committee meeting to review the Company’s New Drug Application (“NDA”) for aficamten. On\u00a0May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten’s NDA from\u00a0September 26, 2025\u00a0to\u00a0December 26, 2025\u00a0in order to review a Risk Evaluation and Mitigation Strategy (“REMS”) submitted at the FDA’s request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA. Then, on\u00a0May 6, 2025, Chief Executive Officer\u00a0Robert I. Blum\u00a0acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. These misleading statements and delayed disclosures caused the company and its shareholders significant harm.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased<\/strong>
\n Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to <\/strong>
\n December 27, 2023,<\/strong>
\n and still hold shares today, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong> $CYTK #Cytokinetics #CYTK<\/p>\n

\n
\n Lifecore Biomedical, Inc. (NASDAQ: LFCR)<\/u>
\n <\/strong>
\n
\n – Securities Fraud Class Action Reaches Settlement:<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. You are encouraged to visit https:\/\/grabarlaw.com\/the-latest\/lifecore-shareholder-investigation\/<\/a>, contact Joshua Grabar at jgrabar@grabarlaw.com<\/a>, or call 267-507-6085. <\/p>\n

WHY?<\/strong>A recently filed federal securities class action against Lifecore Biomedical, Inc. (NASDAQ: LFCR) and certain of its officers <\/strong>has reached a settlement<\/u><\/strong>.\u00a0 \u00a0The underlying class action Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) Lifecore maintained deficient internal controls over financial reporting; (ii) as a result, the Company issued several financial statements that were inaccurate and would need to be restated; (iii) Lifecore’s purported remediation efforts with respect to the foregoing deficiencies were ineffective; (iv) all of the foregoing impaired Lifecore’s ability to timely file periodic reports with the SEC in compliance with NASDAQ listing requirements; (v) accordingly, the Company’s financial position and\/or prospects were materially overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.<\/p>\n

In November 2025, the Company and individual defendants entered into an agreement in principle with the plaintiffs to settle the class action.<\/strong><\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased<\/strong>
\n Lifecore Biomedical, Inc. (NASDAQ: LFCR)<\/strong>
\n shares prior to <\/strong>
\n October 7, 2020,<\/strong>
\n and still hold shares today, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/lifecore-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>
\n
#LFCR $LFCR #Lifecore<\/p>\n

\n
\n Molina Healthcare, Inc. <\/u>
\n <\/strong>
\n
\n (NYSE: MOH)<\/u>
\n <\/strong>
\n :<\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Molina Healthcare, Inc. (NYSE: MOH). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased <\/strong>
\n Molina Healthcare, Inc. <\/strong>
\n (NYSE: MOH)<\/strong>
\n , <\/strong>
\n shares prior to <\/strong>
\n February 5, 2025<\/strong>
\n and still hold shares today, <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/molina-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085 to learn more. <\/strong>\n <\/p>\n

\n WHY?<\/strong> As alleged in an underlying securities fraud class action complaint, Molina Healthcare, Inc. (NYSE: MOH), through certain of its officers, failed to disclose: (1) material, adverse facts concerning Molina Healthcare’s “medical cost trend assumptions”; (2) that Molina Healthcare was experiencing a “dislocation between premium rates and medical cost trend”; (3) that Molina Healthcare’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services”; and (4) as a result, Molina Healthcare’s financial guidance for fiscal year 2025 was substantially likely to be cut.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased <\/strong>
\n Molina Healthcare, Inc. <\/strong>
\n (NYSE: MOH)<\/strong>
\n , <\/strong>
\n shares prior to <\/strong>
\n February 5, 2025<\/strong>
\n and still hold shares today, <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/molina-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>\u00a0\u00a0 $MOH #Molina #MOH<\/p>\n

\n
\n Synopsys, Inc. (NASDAQ: SNPS):<\/u>
\n <\/strong>\n <\/p>\n

Grabar Law Office is investigating claims on behalf of shareholders of Synopsys, Inc. (NASDAQ: SNPS). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.<\/p>\n

\n If you purchased <\/strong>
\n Synopsys (NASDAQ: SNPS) shares prior to December 4, 2024, or acquired Synopsys shares <\/strong>
\n in<\/strong>
\n exchange for shares of Ansys, Inc. (\u201cAnsys\u201d) common stock<\/strong>
\n , <\/strong>
\n you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong>
\n Please visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/synopsys-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call us at 267-507-6085. <\/strong><\/p>\n

WHY?<\/strong> As alleged in a recently filed underlying securities fraud class action complaint, on March 14, 2024, Synopsys (NASDAQ: SNPS) filed with the SEC a registration statement for the acquisition of ANSYS Inc. which was declared effective on April 17, 2024. On April 17, 2024, Synopsys filed with the SEC a prospectus for the Acquisition of ANSYS. The Acquisition Materials stated that ANSYS shareholders would receive $197.00 in cash and 0.345 shares of Synopsys common stock in exchange for each share of ANSYS they held at the time of the merger.\u00a0\u00a0 Unbeknownst to investors, leading up to and at the time of the Acquisition, Synopsys\u2019 historical revenue and profit growth as represented in their Acquisition Materials were artificially inflated by the Company\u2019s unsustainable business practices. Specifically, it is alleged that Defendants misled investors by failing to disclose the following adverse facts: (1) the Company\u2019s growing emphasis on artificial intelligence (\u201cAI\u201d) customers, who require more customization, was weakening the economics of its Design IP business; (2) as a result, certain of the Company\u2019s road map and resource choices were unlikely to achieve their intended outcomes; (3) these issues were materially harming the Company\u2019s financial performance; and (4) as a result of the foregoing, Defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects that when made were materially misleading and\/or lacked a reasonable basis.<\/p>\n

On September 9, 2025, Synopsys released its Q3 2025 results and acknowledged, for the first time that its Design IP business had \u201cunderperformed expectations,\u201d design IP revenue had fallen 8% year-over-year, and the Company would need to \u201cpivot\u201d its road map and IP resources toward stronger-growth areas. Synopsys also revealed that several anticipated IP deals had not materialized and that issues involving a major foundry customer had contributed to the shortfall. The market reacted swiftly on this news with the stock price plunging 35.8% overnight, falling from $604.37 to $387.78 per share, erasing billions in market capitalization.<\/p>\n

\n WHAT YOU CAN DO NOW:<\/strong>
\n If you purchased <\/strong>
\n Synopsys (NASDAQ: SNPS) shares prior to December 4, 2024, or acquired Synopsys shares <\/strong>
\n in<\/strong>
\n exchange for shares of Ansys, Inc. common stock<\/strong>
\n , <\/strong>
\n you are encouraged to visit <\/strong>
\n
\n https:\/\/grabarlaw.com\/the-latest\/synopsys-shareholder-investigation\/<\/strong>
\n <\/a>
\n , contact Joshua Grabar at <\/strong>
\n
\n jgrabar@grabarlaw.com<\/strong>
\n <\/a>
\n , <\/strong>
\n or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.<\/strong> $SNPS #Synopsys #SNPS<\/p>\n

\n Attorney Advertising Disclaimer<\/a>\n <\/p>\n

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: \u00a0267-507-6085
Email: jgrabar@grabarlaw.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or call 267-507-6085. WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its … <\/p>\n

Continue reading “Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-925442","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImportant Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or call 267-507-6085. WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its … Continue reading "Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T15:03:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf\",\"datePublished\":\"2026-01-08T15:03:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/\"},\"wordCount\":1509,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/\",\"name\":\"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=\",\"datePublished\":\"2026-01-08T15:03:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/","og_locale":"en_US","og_type":"article","og_title":"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","og_description":"PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https:\/\/grabarlaw.com\/the-latest\/cytokinetics-shareholder-investigation\/ , contact Joshua Grabar at jgrabar@grabarlaw.com , or call 267-507-6085. WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its … Continue reading \"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-08T15:03:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf","datePublished":"2026-01-08T15:03:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/"},"wordCount":1509,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/","name":"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=","datePublished":"2026-01-08T15:03:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjI4NCM3MzUxNDQ0IzIyMDEyNzA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/important-notice-to-long-term-shareholders-of-cytokinetics-inc-nasdaq-cytk-lifecore-biomedical-inc-nasdaq-lfcr-molina-healthcare-inc-nyse-moh-and-synopsys-inc-nasdaq-snps-graba\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925442","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=925442"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925442\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=925442"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=925442"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=925442"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}